Sarah Cole

Sarah is CEO at ISCARNA Therapeutics, a new biotech focused on developing innovative therapeutics for age-related disease. With over 20 years’ experience in R & D and the venture capital funding of biotech firms, Sarah has established, operationalised, and led early-stage biotechs. With a record of successful deal-making, Sarah is a recognised thought-leader in strategic development, pipeline creation, and the critical evaluation of potential business opportunities. Sarah holds a Ph.D. from the University of Cambridge.